Peptide vaccines in cancer-old concept revisited.

Peptide vaccines in cancer-old concept revisited.
Curr Opin Immunol. 2016 Dec 08;45:1-7
Authors: Kumai T, Kobayashi H, Harabuchi Y, Celis E
Abstract
Synthetic peptide vaccines aim to elicit and expand tumor-specific T cells capable of controlling or eradicating the tumor. Despite the high expectations based on preclinical studies, the results of clinical trials using peptide vaccines have been disappointing. Thus, many researchers in the field have considered peptide vaccines as outdated and no longer viable for cancer therapy. However, recent progress in understanding the critical roles of immune adjuvants, modes of vaccine administration and T cell dynamics has lead to a rebirth of this approach and reconsidering the use of peptide vaccines for treating malignant disorders.
PMID: 27940327 [PubMed - as supplied by publisher]

Source: Current Opinion in Immunology - December 7, 2016 Category: Allergy & Immunology Authors: Kumai T, Kobayashi H, Harabuchi Y, Celis E Tags: Curr Opin Immunol Source Type: research